Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Vaxcyte, Inc. (PCVX)
NASDAQ:PCVX
Vaxcyte (PCVX) Stock Price & Analysis
163 Followers
PCVX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$41.57 - $82.04
Previous Close$60.62
Volume660.97K
Average Volume (3M)845.05K
Market Cap
$6.59B
Enterprise Value$5.34B
Total Cash (Recent Filing)$1.27B
Total Debt (Recent Filing)$13.81M
Price to Earnings (P/E)-14.4
Beta0.89
Next Earnings
May 06, 2024EPS Estimate
-$1.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.21
Shares Outstanding108,407,730
10 Day Avg. Volume625,680
30 Day Avg. Volume845,046
Standard Deviation0.18
R-Squared0.06
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)5.44
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-13.10
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-15.85
Forecast
1Y Price Target
$102.80Price Target Upside69.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
Vaxcyte News
Bulls Say, Bears Say
Bulls Say
Financial OutlookAnalyst raises long-term revenue projections based on higher vaccine odds of success, factoring in increased spending, reflecting a potentially stronger financial position.
Market PotentialIncreased market penetration projections for VAX-31 to 90% in infants and 65% in adults over 65, indicating strong future revenue streams for the company.
Product DevelopmentOngoing clinical development of VAX-24 and VAX-31 shows progress in the company's pipeline, suggesting a forward momentum in bringing new vaccines to market.
Bears Say
Clinical Development RisksThe somewhat experimental design of PCV21 and the decision to swap serotypes could lead to a resurgence of less prevalent serotypes if they are not included in the vaccine.
Financial HealthHigher than expected cash burn in the 4Q, with substantial increases in R&D investments forecasted.
Product EfficacyThe absence of serotype 4 in V116 could suggest a limitation in the vaccine's coverage compared to existing options.
---
Ownership Overview
18.43% Insiders
39.27% Mutual Funds
15.14% Other Institutional Investors
27.16% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
PCVX FAQ
What was Vaxcyte, Inc.’s price range in the past 12 months?
Vaxcyte, Inc. lowest stock price was $41.57 and its highest was $82.04 in the past 12 months.
What is Vaxcyte, Inc.’s market cap?
Currently, no data Available
When is Vaxcyte, Inc.’s upcoming earnings report date?
Vaxcyte, Inc.’s upcoming earnings report date is May 06, 2024 which is in 17 days.
How were Vaxcyte, Inc.’s earnings last quarter?
Vaxcyte, Inc. released its earnings results on Feb 27, 2024. The company reported -$1.83 earnings per share for the quarter, missing the consensus estimate of -$1.054 by -$0.776.
Is Vaxcyte, Inc. overvalued?
According to Wall Street analysts Vaxcyte, Inc.’s price is currently Undervalued.
Does Vaxcyte, Inc. pay dividends?
Vaxcyte, Inc. does not currently pay dividends.
What is Vaxcyte, Inc.’s EPS estimate?
Vaxcyte, Inc.’s EPS estimate is -$1.13.
How many shares outstanding does Vaxcyte, Inc. have?
Vaxcyte, Inc. has 108,759,445 shares outstanding.
What happened to Vaxcyte, Inc.’s price movement after its last earnings report?
Vaxcyte, Inc. reported an EPS of -$1.83 in its last earnings report, missing expectations of -$1.054. Following the earnings report the stock price went down -7.329%.
Which hedge fund is a major shareholder of Vaxcyte, Inc.?
Among the largest hedge funds holding Vaxcyte, Inc.’s share is RA Capital Management. It holds Vaxcyte, Inc.’s shares valued at 496M.
---
Vaxcyte Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$102.80 (69.58% Upside)
$102.80 (69.58% Upside)
Blogger Sentiment
Bullish
PCVX Sentiment 100%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 106.2K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $199.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 3.4%
Last 30 Days ▲ 8.1%
Last 30 Days ▲ 8.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
47.44%
12-Months-Change
Fundamentals
Return on Equity
-36.67%
Trailing 12-Months
Asset Growth
39.93%
Trailing 12-Months
Company Description
Vaxcyte, Inc.
Vaxcyte Inc is a vaccine company seeking to improve global health by developing novel vaccines to treat patients suffering from most common and deadly diseases.
---
PCVX Company Deck
---
PCVX Earnings Call
Q4 2024
0:00 / 0:00
---
PCVX Stock 12 Months Forecast
Average Price Target
$102.80
▲(69.58% Upside)
Technical Analysis
Best Analysts Covering PCVX
1 Year
1 Year Success Rate
9/10 ratings generated profit
1 Year Average Return
+32.57%
reiterated a buy rating 2 months ago
Copying David Risinger's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +32.57% per trade.
---